Cardiac mechanisms for low aerobic power in anthracycline treated, older, long-term breast cancer survivors

Rhys I. Beaudry, Mark J. Haykowsky, James P. MacNamara, Wesley J. Tucker, Roshni Rao, Barbara B Haley, Satyam Sarma

Research output: Contribution to journalArticlepeer-review

Abstract

Breast cancer survivors have reduced peak aerobic capacity (VO2peak) which may be related to latent or lingering chemotherapy induced cardiac damage. Nine, older (67 ± 3 years), long-term survivors (9.8 years) of anthracycline based chemotherapy and age- and sex-matched healthy controls were recruited and tested to determine whether: i) VO2peak remains reduced in long-term survivorship; and ii) reductions in VO2peak are due to cardiac dysfunction. VO2peak was significantly reduced in breast cancer survivors relative to healthy controls (15.9 ± 2.0 vs 19.9 ± 3.1 ml/kg/min, p = 0.006), however the heart rate and stroke volume responses to exercise were normal (heart rate reserve; 88 ± 9 vs 85 ± 10 bpm, p = 0.62: stroke volume reserve; 13 ± 6 vs 13 ± 9 ml,p = 0.94). These findings indicate low-normal ventricular size in long-term breast cancer survivors, but normal reserve function.

Original languageEnglish (US)
Article number8
JournalCardio-Oncology
Volume8
Issue number1
DOIs
StatePublished - Dec 2022

Keywords

  • Aerobic capacity
  • Anthracycline
  • Breast cancer
  • Cardiac function
  • Exercise
  • VO

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Oncology

Fingerprint

Dive into the research topics of 'Cardiac mechanisms for low aerobic power in anthracycline treated, older, long-term breast cancer survivors'. Together they form a unique fingerprint.

Cite this